StocksFundsScreenerSectorsWatchlists
CRSP

CRSP - CRISPR Therapeutics AG Stock Price, Fair Value and News

55.05USD-1.11 (-1.98%)Market Closed

Market Summary

CRSP
USD55.05-1.11
Market Closed
-1.98%

CRSP Alerts

  • 3 major insider sales recently.

CRSP Stock Price

View Fullscreen

CRSP RSI Chart

CRSP Valuation

Market Cap

4.4B

Price/Earnings (Trailing)

-28.77

Price/Sales (Trailing)

11.9

EV/EBITDA

-30.79

Price/Free Cashflow

-16.38

CRSP Price/Sales (Trailing)

CRSP Profitability

EBT Margin

-40.60%

Return on Equity

-8.16%

Return on Assets

-6.89%

Free Cashflow Yield

-6.11%

CRSP Fundamentals

CRSP Revenue

Revenue (TTM)

371.2M

Rev. Growth (Yr)

183.52%

Rev. Growth (Qtr)

-100%

CRSP Earnings

Earnings (TTM)

-153.6M

Earnings Growth (Yr)

180.8%

Earnings Growth (Qtr)

179.67%

Breaking Down CRSP Revenue

Last 7 days

-9.3%

Last 30 days

-24.5%

Last 90 days

-11.2%

Trailing 12 Months

10.3%

How does CRSP drawdown profile look like?

CRSP Financial Health

Current Ratio

17.54

CRSP Investor Care

Shares Dilution (1Y)

2.07%

Diluted EPS (TTM)

-1.94

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023643.1M552.5M461.8M371.2M
2022824.3M00733.7M
2021646.9M736.3M825.6M915.0M
20200378.9M468.3M557.6M
20192.1M97.9M193.8M289.6M
201831.5M22.1M12.6M3.1M
20177.4M10.2M11.0M41.0M
20161.2M2.1M3.1M5.2M
2015000247.0K

Tracking the Latest Insider Buys and Sells of CRISPR Therapeutics AG

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 15, 2024
kulkarni samarth
acquired
374,408
19.12
19,582
chief executive officer
Apr 15, 2024
kulkarni samarth
sold
-1,173,230
59.9138
-19,582
chief executive officer
Mar 15, 2024
kulkarni samarth
acquired
764,800
19.12
40,000
chief executive officer
Mar 15, 2024
kulkarni samarth
sold
-2,899,260
72.4814
-40,000
chief executive officer
Mar 15, 2024
prasad raju
sold
-256,160
72.69
-3,524
chief financial officer
Mar 14, 2024
prasad raju
acquired
-
-
10,000
chief financial officer
Mar 12, 2024
kulkarni samarth
sold
-341,159
74.44
-4,583
chief executive officer
Mar 12, 2024
kasinger james r.
sold
-85,308
74.44
-1,146
general counsel and secretary
Mar 11, 2024
kulkarni samarth
acquired
-
-
9,000
chief executive officer
Mar 11, 2024
kulkarni samarth
sold
-767,104
78.26
-9,802
chief executive officer

1–10 of 50

Which funds bought or sold CRSP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 18, 2024
WOLFF WIESE MAGANA LLC
unchanged
-
556
6,816
0.01%
Apr 18, 2024
InTrack Investment Management Inc
new
-
521,951
521,951
0.39%
Apr 18, 2024
Allspring Global Investments Holdings, LLC
added
113
3,061,950
5,379,460
0.01%
Apr 18, 2024
Miracle Mile Advisors, LLC
unchanged
-
28,067
344,072
0.01%
Apr 18, 2024
SeaCrest Wealth Management, LLC
new
-
229,290
229,290
0.03%
Apr 18, 2024
SteelPeak Wealth, LLC
added
129
419,085
698,845
0.04%
Apr 18, 2024
SJS Investment Consulting Inc.
unchanged
-
2,302
28,219
0.01%
Apr 18, 2024
ARK Investment Management LLC
reduced
-4.44
21,622,900
555,983,000
3.85%
Apr 18, 2024
Koss-Olinger Consulting, LLC
sold off
-100
-1,876,000
-
-%
Apr 18, 2024
Arlington Financial Advisors, LLC
unchanged
-
23,702
290,566
0.06%

1–10 of 48

Are Funds Buying or Selling CRSP?

Are funds buying CRSP calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CRSP
No. of Funds

Unveiling CRISPR Therapeutics AG's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 10, 2024
capital international investors
10.2%
8,223,994
SC 13G/A
Feb 12, 2024
nikko asset management americas, inc.
4.24%
3,369,762
SC 13G/A
Feb 09, 2024
capital international investors
8.1%
6,420,736
SC 13G/A
Feb 05, 2024
sumitomo mitsui trust holdings, inc.
4.24%
3,369,762
SC 13G/A
Jan 29, 2024
ark investment management llc
10.75%
8,536,104
SC 13G/A
Jan 10, 2024
ark investment management llc
10.75%
8,536,104
SC 13G/A
Apr 11, 2023
ark investment management llc
10.16%
7,990,188
SC 13G/A
Feb 13, 2023
capital international investors
7.1%
5,560,492
SC 13G
Feb 10, 2023
nikko asset management americas, inc.
5.11%
4,006,476
SC 13G/A
Feb 10, 2023
ark investment management llc
10.00%
7,829,932
SC 13G/A

Recent SEC filings of CRISPR Therapeutics AG

View All Filings
Date Filed Form Type Document
Apr 17, 2024
4
Insider Trading
Apr 15, 2024
144
Notice of Insider Sale Intent
Apr 10, 2024
SC 13G/A
Major Ownership Report
Apr 09, 2024
ARS
ARS
Apr 09, 2024
DEF 14A
DEF 14A
Apr 09, 2024
DEFA14A
DEFA14A
Mar 27, 2024
PRE 14A
PRE 14A
Mar 22, 2024
4
Insider Trading
Mar 22, 2024
4
Insider Trading
Mar 22, 2024
4
Insider Trading

Peers (Alternatives to CRISPR Therapeutics AG)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
38.7B
6.8B
-1.66% -28.18%
-8.22
5.66
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.2B
1.8B
-2.46% -28.84%
-41.3
9.94
76.23% 61.08%
16.7B
2.4B
4.57% -8.46%
99.75
6.91
15.42% 18.43%
11.8B
3.7B
-10.11% -29.11%
19.67
3.18
8.87% 75.42%
MID-CAP
5.7B
396.6M
-14.37% -42.33%
-10.84
14.45
425.83% 18.94%
4.4B
-
-13.59% 50.21%
-6.66
60.35
54.84% -34.79%
3.2B
270.6M
-13.81% -4.67%
-13.46
11.9
440.80% -27.84%
2.8B
726.4M
-9.91% -15.82%
-45.19
3.81
40.45% 71.62%
2.8B
240.7M
-20.67% -25.33%
-9.33
12.18
-1.03% -92.09%
SMALL-CAP
1.8B
398.2M
-10.64% -8.42%
24.94
4.47
85.90% -14.05%
558.4M
983.7M
-17.39% -51.52%
-1.02
0.57
-50.36% 17.16%
409.4M
881.7K
-0.38% 387.14%
-9.18
466.16
-77.61% -5.33%
226.2M
4.9M
-10.29% -2.81%
-1.67
46.49
-54.97% 51.71%
6.0M
2.1M
59.81% 33.59%
-0.22
2.14
-13.45% 66.37%

CRISPR Therapeutics AG News

Latest updates
Yahoo Finance17 Apr 202404:58 pm
Yahoo Finance17 Apr 202401:00 pm

CRISPR Therapeutics AG Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q1
Revenue-201,206,000-70,000,000100,000,00070,966,33341,932,66712,899,000824,000900,701,000735,964,000571,227,000406,490,000241,753,00077,016,000211,928,000106,128,000328,000115,000563,0001,088,00016,706,500
Operating Expenses-0.6%131,623,000132,411,000165,223,000164,487,000131,547,000176,912,000158,597,000129,673,000138,083,000115,082,000108,131,00092,547,00080,733,00066,033,00072,765,00055,301,00048,751,00045,343,00049,995,00038,374,00028,355,000
  S&GA Expenses-9.9%16,479,00018,291,00019,032,00022,360,00021,169,00028,021,00023,168,00023,709,00028,806,00024,517,00023,305,00021,539,00021,353,00017,272,00015,519,00015,768,00014,929,00016,542,00010,175,00012,741,0008,836,000
  R&D Expenses4.9%95,144,00090,698,000101,555,00099,935,000103,555,000118,245,000103,605,00083,500,00082,332,00070,620,00036,801,00071,008,00059,380,00048,761,00057,246,00039,533,00033,822,00028,801,00039,820,00025,633,00019,519,000
EBITDA Margin52.0%-0.35-0.74-0.44-0.55-0.680.370.431.491.60-1.32-----------
Income Taxes-46.1%222,000412,000900,0001,320,000-9,450,5003,600,000-2,232,500-595,0004,100,000600,000-169,000200,000400,00026,000274,00085,00085,000234,000137,00096,00086,000
Earnings Before Taxes180.2%89,580,000-111,740,000-76,817,000-51,745,000-120,051,000-175,609,000-143,501,000-127,748,000763,368,000-112,588,000-107,186,000-92,239,000-79,277,00030,546,000138,697,000-53,614,000-48,323,000-47,356,000-50,574,000-38,284,000-28,214,000
EBT Margin48.0%-0.41-0.78-0.46-0.58-0.710.350.411.441.56-1.35-----------
Net Income179.7%89,347,000-112,152,000-77,740,000-53,065,000-110,575,000-179,217,000-141,248,000-127,153,000759,225,000-113,163,000-107,039,000-92,439,000-79,656,00030,542,000138,423,000-53,699,000-48,408,000-47,590,000-50,711,000-38,380,000-
Net Income Margin45.9%-0.41-0.77-0.45-0.57-0.710.340.411.421.54-1.35-----------
Free Cashflow-130.6%-96,811,000-41,974,000-136,800,0005,740,000-119,519,000-150,589,000-95,221,000-118,378,000778,553,000-107,687,000-----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets6.8%2,2302,0872,1972,2442,2432,3532,4632,6062,7522,8222,9001,9581,8281,4851,0471,0071,067721494498489
  Current Assets8.4%1,9081,7611,8601,9081,8531,9332,1072,2612,4182,5192,6211,8321,7171,391966929988664438450466
    Cash Equivalents-26.2%3895284453442124944976849231,0121,6471,1261,1691,041945890944630428438457
  Net PPE-2.7%15215615916216416616515713810675.0052.0042.0038.0034.0032.0031.0021.0020.0019.0019.00
Liabilities-3.4%34735938138936839937336135230929615216414213612112712912711897.00
  Current Liabilities-2.2%10911113314712115112011412096.0010083.0094.0084.0075.0055.0057.0080.0031.0028.0028.00
Shareholder's Equity9.0%1,8831,7281,8161,8551,8751,9542,0912,2452,3992,5132,6041,8051,6641,343911886939592368380392
  Retained Earnings8.2%-999-1,089-976-899-846-735-560-375-195-54.6772.00-686-573-466-374-294-224-255-393-339-291
  Additional Paid-In Capital2.0%2,8782,8212,7992,7612,7352,7092,6702,6352,5982,5662,5302,4902,2361,8081,2831,1791,162846760718682
Shares Outstanding0.8%80.0079.0079.0079.0079.0078.0078.0077.0076.0076.0075.0075.00---------
Float---4,100---4,300---11,400---4,500---2,500--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-141.1%-96,073-39,856-133,2458,799-113,328-105,218-141,956-135,239-86,038-81,329807,002-100,663-81,212-75,700-29,279-52,1753,376133,420-36,382-43,737-28,372
  Share Based Compensation-7.8%18,42019,96821,76520,87522,80524,54524,85225,74525,76826,19928,33122,09218,93017,24015,69714,15111,85711,34311,1869,67113,025
Cashflow From Investing-167.1%-81,453121,348216,923117,829-175,53287,464-56,072-114,515-8,716-565,180-293,636-167,898-204,244-330,330-3,605-2,9917,057-2,461-2,174-1,097-1,000
Cashflow From Financing2402.5%38,9391,55616,7655,4042,47815,11210,35310,6496,29910,2128,443225,991412,627512,88889,5051,132304,71870,88529,65425,726-1,269

CRSP Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue:   
Total revenue$ 371,206$ 1,198$ 914,963
Operating expenses:   
Research and development387,332461,645340,567
General and administrative76,162102,46499,690
Collaboration expense, net130,250110,250101,178
Total operating expenses593,744674,359541,435
(Loss) income from operations(222,538)(673,161)373,528
Other income   
Other income, net71,81622,6616,003
Total other income, net71,81622,6616,003
Net income (loss) before income taxes(150,722)(650,500)379,531
(Provision) benefit for income taxes(2,888)325(1,870)
Net (loss) income(153,610)(650,175)377,661
Foreign currency translation adjustment73(80)(11)
Unrealized gain (loss) on marketable securities17,487(10,500)(4,973)
Comprehensive (loss) income$ (136,050)$ (660,755)$ 372,677
Net (loss) income per common share - basic$ (1.94)$ (8.36)$ 4.97
Basic weighted-average common shares outstanding79,220,93077,746,57575,948,686
Net (loss) income per common share - diluted$ (1.94)$ (8.36)$ 4.7
Diluted weighted-average common shares outstanding79,220,93077,746,57580,393,496
Collaboration Revenue [Member]   
Revenue:   
Total revenue$ 370,000$ 436$ 913,081
Grant Revenue [Member]   
Revenue:   
Total revenue$ 1,206$ 762$ 1,882

CRSP Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 389,477$ 211,885
Marketable securities1,304,2151,603,433
Accounts receivable200,0000
Prepaid expenses and other current assets14,38637,708
Total current assets1,908,0781,853,026
Property and equipment, net151,945163,634
Marketable securities, non-current1,97353,130
Intangible assets, net1671
Restricted cash11,59111,635
Operating lease assets153,993156,921
Other non-current assets1,9754,640
Total assets2,229,5712,243,057
Current liabilities:  
Accounts payable38,14727,428
Accrued expenses45,33577,682
Deferred revenue, current4,1050
Accrued tax liabilities438135
Operating lease liabilities15,62515,842
Other current liabilities5,14120
Total current liabilities108,791121,107
Deferred revenue, non-current14,01212,323
Operating lease liabilities, net of current portion223,007228,179
Other non-current liabilities9585,969
Total liabilities346,768367,578
Commitments and contingencies (Note 9)
Shareholders’ equity:  
Common shares, CHF 0.03 par value, 126,536,183 and 150,347,467 shares authorized at December 31, 2023 and 2022, respectively, 80,214,694 and 78,692,766 shares issued at December 31, 2023 and 2022, respectively, 80,044,378 and 78,512,450 shares outstanding at December 31, 2023 and 2022,respectively2,4972,441
Treasury shares, at cost, 170,316 and 180,316 shares at December 31, 2023 and 2022, respectively(62)(63)
Additional paid-in capital2,878,1552,734,838
Accumulated deficit(999,700)(846,090)
Accumulated other comprehensive income (loss)1,913(15,647)
Total shareholders’ equity1,882,8031,875,479
Total liabilities and shareholders’ equity$ 2,229,571$ 2,243,057
CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
 CEO
 WEBSITEcrisprtx.com
 INDUSTRYBiotechnology
 EMPLOYEES458

CRISPR Therapeutics AG Frequently Asked Questions


What is the ticker symbol for CRISPR Therapeutics AG? What does CRSP stand for in stocks?

CRSP is the stock ticker symbol of CRISPR Therapeutics AG. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CRISPR Therapeutics AG (CRSP)?

As of Fri Apr 19 2024, market cap of CRISPR Therapeutics AG is 4.42 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRSP stock?

You can check CRSP's fair value in chart for subscribers.

What is the fair value of CRSP stock?

You can check CRSP's fair value in chart for subscribers. The fair value of CRISPR Therapeutics AG is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CRISPR Therapeutics AG is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRSP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CRISPR Therapeutics AG a good stock to buy?

The fair value guage provides a quick view whether CRSP is over valued or under valued. Whether CRISPR Therapeutics AG is cheap or expensive depends on the assumptions which impact CRISPR Therapeutics AG's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRSP.

What is CRISPR Therapeutics AG's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, CRSP's PE ratio (Price to Earnings) is -28.77 and Price to Sales (PS) ratio is 11.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRSP PE ratio will change depending on the future growth rate expectations of investors.